NAVIDEA BIOPHARMACEUTICALS I (NAVB)

US63937X2027 - Common Stock

0.0779  0 (-2.99%)

Full estimates are only available for subscribed users, you can see which data is available below.

Examples of complete estimate data are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional estimates and surprises .

Yearly Revenue, EBIT, EBITDA and EPS Analyst Estimates
2020 2021 2022
Revenue
YoY % growth
915.01K
39.10%		531.51K
-41.91%		65.65K
-87.65%
EBITDA
YoY % growth
-10.641M
1.64%		-11.983M
-12.62%		-13.955M
-16.45%
EBIT
YoY % growth
-10.711M
2.29%		-12.06M
-12.60%		-14.051M
-16.50%
Operating Margin
-1,170.61%-2,269.09%-21,402.74%
EPS
YoY % growth
-0.48
40.00%		-0.40
16.67%		N/A

All data in USD

Quarterly Revenue, EBIT, EBITDA and EPS Analyst Estimates
EPS
Q2Q % growth
Revenue
Q2Q % growth
EBITDA
Q2Q % growth
EBIT
Q2Q % growth

All data in USD

Recent Earnings VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q3 2021
Q2Q % growth		 -0.08
38.46%		-0.110.0328.70%
Q2 2021
Q2Q % growth		 -0.09
18.18%		-0.08-0.01-10.29%
Q1 2021
Q2Q % growth		 -0.11
15.38%		-0.08-0.03-34.80%
Q4 2020
Q2Q % growth		 -0.11
26.67%		-0.120.0110.13%
Recent Revenue VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q3 2021
Q2Q % growth		 96.38K
-64.09%		96.38K∞%
Q2 2021
Q2Q % growth		 261.05K
-3.71%		612K-350.95K-57.34%
Q1 2021
Q2Q % growth		 123.74K
-20.82%		612K-488.26K-79.78%
Q4 2020
Q2Q % growth		 219.25K
83.78%		612K-392.75K-64.17%
EPS and Revenue Revisions
Next Q (1 month) Next Q (3 month) Next Year (1 month) Next Year (3 month)
EPSN/A N/A N/A N/A
RevenueN/A N/A N/A N/A